Results 171 to 180 of about 9,526,180 (306)

Identification of Epigenetic Alteration of the IFI44L Gene in B Cells of Sjogren’s Syndrome as a Clinical Biomarker and Molecular Significance

open access: yesJournal of Inflammation Research
Kaiyuan Zhang,1,* Ziyue Luo,2,* Xinyi Yao,2 Dingqi Lu,2 Tao Hong,3 Xinchao Zhu,2 Mei Chen,2 Xinchang Wang4 1School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310053, People’s Republic of China ...
Zhang K   +7 more
doaj  

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

open access: yesMolecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan   +9 more
wiley   +1 more source

The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions. [PDF]

open access: yesInt J Mol Sci
Mailaender F   +4 more
europepmc   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

B cell-reactive neoantigens boost antitumor immunity. [PDF]

open access: yesSci Adv
Kim JY   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy